Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Revance Therapeutics, Inc. - Common Stock (NQ: RVNC )

3.650 UNCHANGED
Last Price Updated: 4:00 PM EST, Feb 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 3.650
Bid (Size) 3.650 (47)
Ask (Size) 3.660 (542)
Prev. Close 3.650
Today's Range 3.650 - 3.650
52wk Range 2.300 - 7.560
Shares Outstanding 71,829,718
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
REVANCE THERAPEUTICS INVESTOR ALERT: Kaplan Fox Alerts Investors of a Class Action Deadline on March 4, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
REVANCE THERAPEUTICS INVESTOR ALERT: Kaplan Fox Alerts Investors of a Class Action Deadline on March 4, 2025
NEW YORK - February 15, 2025 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Revance Therapeutics, Inc. (“Revance” or the “Company”) (NASDAQ:... 
Via TheNewswire.com
Topics Lawsuit
Exposures Financial Legal

Performance

YTD
+19.28%
+19.28%
1 Month
+11.62%
+11.62%
3 Month
-8.52%
-8.52%
6 Month
-44.78%
-44.78%
1 Year
-34.35%
-34.35%

More News

Read More
RVNC SHAREHOLDER ALERT: Deadline to Lead in Securities Fraud Lawsuit Against Revance Therapeutics, Inc. (RVNC) is March 4, 2025 - Contact Kaplan Fox
Via TheNewswire.com
Topics Fraud Lawsuit
Exposures Financial Legal
RVNC SHAREHOLDER ALERT: Deadline to Lead in Securities Fraud Lawsuit Against Revance Therapeutics, Inc. (RVNC) is March 4, 2025 - Contact Kaplan Fox
Via NewMediaWire
Topics Fraud Lawsuit
Exposures Financial Legal
Kaplan Fox Alerts Revance Therapeutics Investors to a Securities Class Action Lawsuit - Deadline is March 4, 2025
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
Kaplan Fox Alerts Revance Therapeutics Investors to a Securities Class Action Lawsuit - Deadline is March 4, 2025
Via TheNewswire.com
Topics Lawsuit
Exposures Financial Legal
RVNC DEADLINE ALERT: Kaplan Fox Reminds Investors of a Class Action Lawsuit Against Revance Therapeutics, Inc. (RVNC) and Lead Plaintiff Deadline on March 4, 2025
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
RVNC DEADLINE ALERT: Kaplan Fox Reminds Investors of a Class Action Lawsuit Against Revance Therapeutics, Inc. (RVNC) and Lead Plaintiff Deadline on March 4, 2025
Via TheNewswire.com
Topics Lawsuit
Exposures Financial Legal
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against IIPR, AstraZeneca, FTAI, and Revance and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Crown Laboratories Completes Acquisition of Revance Therapeutics
From Hildred Capital
Via Business Wire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against BioAge, AstraZeneca, FTAI, and Revance and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
RVNC SHAREHOLDER ACTION ALERT: Kaplan Fox Reminds Investors of a Class Action Lawsuit Against Revance Therapeutics, Inc. (RVNC) and Lead Plaintiff Deadline on March 4, 2025
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
RVNC SHAREHOLDER ACTION ALERT: Kaplan Fox Reminds Investors of a Class Action Lawsuit Against Revance Therapeutics, Inc. (RVNC) and Lead Plaintiff Deadline on March 4, 2025
Via TheNewswire.com
Topics Lawsuit
Exposures Financial Legal
RVNC DEADLINE FOR LEADERSHIP is March 4, 2025 in a Securities Fraud Lawsuit - Contact Kaplan Fox
Via NewMediaWire
Topics Fraud Lawsuit
Exposures Financial Legal
RVNC DEADLINE FOR LEADERSHIP is March 4, 2025 in a Securities Fraud Lawsuit - Contact Kaplan Fox
Via TheNewswire.com
Topics Fraud Lawsuit
Exposures Financial Legal
RVNC CLASS ACTION DEADLINE: Kaplan Fox Reminds Investors of a Class Action Lawsuit Against Revance Therapeutics, Inc. (RVNC) and Lead Plaintiff Deadline on March 4, 2025
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
RVNC CLASS ACTION DEADLINE: Kaplan Fox Reminds Investors of a Class Action Lawsuit Against Revance Therapeutics, Inc. (RVNC) and Lead Plaintiff Deadline on March 4, 2025
Via TheNewswire.com
Topics Lawsuit
Exposures Financial Legal
REVANCE THERAPEUTICS DEADLINE FOR LEADERSHIP is March 4, 2025 in a Securities Fraud Lawsuit - Contact Kaplan Fox & Kilsheimer LLP
Via NewMediaWire
Topics Fraud Lawsuit
Exposures Financial Legal
REVANCE THERAPEUTICS DEADLINE FOR LEADERSHIP is March 4, 2025 in a Securities Fraud Lawsuit - Contact Kaplan Fox & Kilsheimer LLP
Via TheNewswire.com
Topics Fraud Lawsuit
Exposures Financial Legal
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against BioAge, Caribou, FTAI, and Revance and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
RVNC DEADLINE: Investors of Revance Therapeutics, Inc. Are Encouraged to Contact Kaplan Fox Before the Lead Plaintiff Deadline on March 4, 2025
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
RVNC DEADLINE: Investors of Revance Therapeutics, Inc. Are Encouraged to Contact Kaplan Fox Before the Lead Plaintiff Deadline on March 4, 2025
Via TheNewswire.com
Topics Lawsuit
Exposures Financial Legal
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against BioAge and Revance and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Crown Laboratories and Revance Amend the A&R Merger Agreement to Increase Offer Price to $3.65 per Share and Extend Existing Tender Offer
From Revance Therapeutics, Inc.
Via Business Wire
RVNC INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Revance Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
From Bronstein, Gewirtz & Grossman
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.